Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
September 17, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Cantor Global Healthcare Conference
September 10, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Second Quarter 2024 Financial Results
August 08, 2024 16:05 ET
|
Kura Oncology, Inc.
– Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 – – Breakthrough Therapy Designation granted for ziftomenib in R/R NPM1-mutant AML – –...
Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
August 08, 2024 07:30 ET
|
Kura Oncology, Inc.
– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses – – Proof-of-concept study evaluating ziftomenib...
Kura Oncology to Report Second Quarter 2024 Financial Results
August 01, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
June 24, 2024 07:30 ET
|
Kura Oncology, Inc.
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology to Participate in Jefferies Global Healthcare Conference
May 29, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
May 14, 2024 07:30 ET
|
Kura Oncology, Inc.
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN...